Compounds for Treatment of Bovine Mastitis
Described herein are methods of treating mastitis in female mammals, e.g., cows, wherein the methods may include administering to mammals in need thereof compounds disclosed herein.
1 . A method of treating mastitis in a female mammal in need thereof, comprising administering to the female mammal having or at risk of having mastitis an effective amount of a compound selected from the group consisting of (E)-N-methyl-N-((2-methyl-1H-indol-3-yl)methyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide; (E)-N-methyl-N-((3-methylbenzofuran-2-yl)methyl)-3-(2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)acrylamide; (E)-N-methyl-N-(3-methylbenzofuran-2-ylmethyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide; and pharmaceutically acceptable salts and esters thereof
2 . The method of claim 1 , wherein the female mammal is a milk producing mammal.
3 . The method of claim 1 , wherein the female mammal is a cow, horse, human, goat, sheep, buffalo, or camel.
4 . A method of treating bovine mastitis in a cow in need thereof, comprising administering to said cow an effective amount of a composition comprising (E)-N-methyl-N-((2-methyl-1H-indol-3-yl)methyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide or a pharmaceutically acceptable salt or ester thereof
5 . A method of treating bovine mastitis in a cow in need thereof, comprising administering to said cow an effective amount of a composition comprising (E)-N-methyl-N-((3-methylbenzofuran-2-yl)methyl)-3-(2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)acrylamide or a pharmaceutically acceptable salt or ester thereof.
6 . The method of claim 1 , wherein the mastitis is caused by a bacterial infection.
7 . The method of claim 6 , wherein the bacterial infection is caused by one or more strains of Staphylococcus aureus.
8 . The method of claim 7 , wherein the bacterial infection is caused by one or more strains of Staphylcoccus Oxford, Staphylococcus aureus WCUH29, Streptococcus pneumoniae ERY 2, Streptococcus pneumoniae 1629, Streptococcus pneumoniae N 1387, Enterococcus faecalis I, Enterococcus faecalis 7, Haemophilus influenzae Q1, Haemophilus influenzae NEMC1, Moraxella Catarrhalis 1502, Escherichia coli 7623 AcrABEFD+, Escherichia coli 120 AcrAB-, Escherichia coli MG1655, or Escherichia coli MG1658.
9 . The method of claim 6 , wherein the bacterial infection is caused by one or more strains of Staphylococcus auereues, Streptococcus dysgalactiae, Streptococcus equinus, Streptococcus agalactiae, Staphylococcus hyicus, Staphylococcus simulans, Staphylococcus epidermidis, Staphylococcus chromogenes or Staphylococcus xylosus.
10 . The method of claim 6 , wherein the bacterial infection is caused by one or more strains of Pseudomonas aeruginosa, Corynebacterium pyogenes, Mycoplasma bovis, Serratia, Candida, E. coli, Klebsiella or Enterobacter.
11 . The method of claim 6 , wherein the S. aureus is methicillin-resistant Staphylococcus aureus.
12 . The method of claim 3 , wherein the compound is administered to the udder of the cow.
13 . The method of claim 1 , wherein the compound is administered orally, rectally, vaginally, subcutaneously, or intravenously.